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Key points  34 
• Heart failure (HF) is characterised by limb and respiratory muscle impairments 35 
that limit functional capacity and quality of life. However, compared to HF with 36 
reduced ejection fraction (HFrEF), skeletal muscle alterations induced by HF 37 
with preserved ejection fraction (HFpEF) remain poorly explored. 38 
• Here we report that HFpEF induces multiple skeletal muscle alterations in the 39 
rat hindlimb, including impaired muscle mechanics related to shortening 40 
velocity, fibre atrophy, capillary loss, and an impaired blood flow response to 41 
contractions that implies a perfusive oxygen delivery limitation.  42 
• We also demonstrate that HFpEF is characterised by diaphragmatic alterations 43 
similar to those caused by denervation — atrophy in Type IIb/IIx (fast/glycolytic) 44 
fibres and hypertrophy in Type I (slow/oxidative) fibres.   45 
• These findings extend current knowledge in HFpEF skeletal muscle physiology, 46 
potentially underlying exercise intolerance, which may facilitate future 47 
therapeutic approaches.  48 




Peripheral skeletal muscle and vascular alterations induced by heart failure with 51 
preserved ejection fraction (HFpEF) remain poorly identified, with limited therapeutic 52 
targets. This study used a cardiometabolic obese HFpEF rat model to 53 
comprehensively phenotype skeletal muscle mechanics, blood flow, 54 
microvasculature, and fibre atrophy.  55 
Lean (n=8) and obese-HFpEF (n=8) ZSF1 rats were compared. Skeletal muscles 56 
(soleus and diaphragm) were assessed for in vitro contractility (isometric and isotonic 57 
properties) alongside indices of fibre-type cross-sectional area, myosin isoform, and 58 
capillarity, and estimated muscle PO2. In situ extensor digitorum longus (EDL) 59 
contractility and femoral blood flow were assessed.  60 
HFpEF soleus demonstrated lower absolute maximal force by 22%, fibre atrophy by 61 
24%, a fibre-type shift from I to IIa, and a 17% lower capillary-to-fibre ratio despite 62 
increased capillary density (all P<0.05) with preserved muscle PO2 (P=0.115) and 63 
isometric specific force (P>0.05). Soleus isotonic properties (shortening velocity and 64 
power) were impaired by up to 17 and 22% respectively (P<0.05), while the magnitude 65 
of the exercise hyperaemia was attenuated by 73% (P=0.012) in line with higher 66 
muscle fatigue by 26% (P=0.079). Diaphragm alterations (P<0.05) included Type IIx 67 
fibre atrophy despite Type I/IIa fibre hypertrophy, with increased indices of capillarity 68 
alongside preserved contractile properties during isometric, isotonic, and cyclical 69 
contractions.  70 
In conclusion, obese-HFpEF rats demonstrated blunted skeletal muscle blood flow 71 
during contractions in parallel to microvascular structural remodelling, fibre atrophy, 72 
and isotonic contractile dysfunction in the locomotor muscles. In contrast, diaphragm 73 
phenotype remained well preserved. This study identifies numerous muscle-specific 74 
impairments that could exacerbate exercise intolerance in obese-HFpEF.   75 
  76 
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Introduction  77 
Increasing prevalence of heart failure with preserved ejection fraction (HFpEF), in the 78 
absence of recognised pharmaceutical treatments, represents one of the biggest 79 
challenges to modern cardiology (Butler et al., 2014; Sharma & Kass, 2014; Fukuta et 80 
al., 2016).  While the primary pathology of HFpEF is of cardiac origin, there is a poor 81 
correlation between heart dysfunction and the main symptom of exercise intolerance 82 
(Haykowsky & Kitzman, 2014), while many clinical trials have shown cardiac-83 
orientated drugs are not associated with beneficial outcomes (Shah et al., 2016). 84 
Recent investigations, therefore, have suggested non-cardiac ‘peripheral’ factors as 85 
major mechanisms limiting functional capacity and quality of life in patients with 86 
HFpEF, with skeletal muscle abnormalities receiving much attention (Adams et al., 87 
2017; Poole et al., 2018; Zamani et al., 2020). For example, animal and human studies 88 
have shown that HFpEF is associated with various skeletal muscle impairments that 89 
are closely associated with exercise intolerance and lower quality of life, including 90 
lower skeletal muscle mass and strength (Bekfani et al., 2016), generalized fibre 91 
atrophy (Bowen et al., 2018), fat infiltration (Haykowsky et al., 2014; Zamani et al., 92 
2020), reduced global capillary-to-fibre ratio (Kitzman et al., 2014; Bowen et al., 2018), 93 
reduced mitochondrial function and content (Bowen et al., 2015; Molina et al., 2016; 94 
Bowen et al., 2017b), disrupted high-energy phosphate metabolism (Bhella et al., 95 
2011b; Weiss et al., 2017), and impaired O2 extraction (Dhakal et al., 2015; Houstis et 96 
al., 2018; Zamani et al., 2020).  97 
 98 
Despite recent progress, our current understanding of the skeletal muscle 99 
pathophysiology in HFpEF at both the structural and functional level is at its infancy, 100 
with only limited and often conflicting experimental data available (Poole et al., 2018). 101 
For example, it remains controversial whether leg muscle arterial blood flow (i.e., 102 
perfusive O2 transport) is impaired during exercise in HFpEF due to a lack of direct 103 
measurements (Hundley et al., 2007; Haykowsky et al., 2013; Lee et al., 2016a; 104 
Weavil et al., 2020), with key studies dependent upon systemic blood sampling 105 
reporting conflicting findings regarding whether a perfusive or diffusive O2 transport 106 
limitation impairs muscle O2 extraction and thus exercise intolerance in HFpEF 107 
(Dhakal et al., 2015; Houstis et al., 2018; Zamani et al., 2020). As such, there remains 108 
a lack of clarity on whether functional indices related to leg blood flow and perfusive 109 
O2 delivery are constrained in HFpEF. Likewise, we also have a limited understanding 110 
5 
 
of the muscle and microvascular structural phenotype that occurs with HFpEF.  For 111 
example, while studies have shown a global fibre atrophy is present alongside a loss 112 
of capillaries-per-fibre (Kitzman et al., 2014; Bowen et al., 2015; Bowen et al., 2017b; 113 
Bowen et al., 2018; Schauer et al., 2020), the degree of atrophy and capillary 114 
rarefaction quantified locally across all fibre isoforms which can be further harnessed 115 
to provide novel estimates of muscle PO2 remains undefined. Furthermore, a 116 
knowledge gap still exists in relation to potential sites of skeletal muscle dysfunction 117 
in HFpEF that include the contribution of neuromuscular transmission vs. excitation-118 
contraction failure and/or the impact on more physiologically-relevant mechanical 119 
measures (i.e., shortening velocity and power), with previous studies performed using 120 
only in vitro isometric contractions under direct-muscle stimulation (Bowen et al., 2015; 121 
Bowen et al., 2017b; Bowen et al., 2018; Schauer et al., 2020).  122 
 123 
Beyond this, the majority of experimental work has been directed towards 124 
characterising the locomotor muscles despite key evidence showing respiratory 125 
muscle dysfunction is linked to exercise intolerance in HFpEF, as shown by non-126 
invasive patient measures (Lavietes et al., 2004; Yamada et al., 2016) and direct 127 
diaphragm contractility measures in experimental models (Bowen et al., 2015; Bowen 128 
et al., 2017b). Similar to limb muscle, however, detailed quantification of diaphragm 129 
fibre-type morphology, capillarity, PO2, and clinically-relevant functional 130 
measurements during cyclical length changes (i.e., as occurs during breathing) remain 131 
largely undefined in HFpEF and are unlikely to follow a similar response to the 132 
locomotor muscles.  133 
 134 
The present study, therefore, aimed to provide a more comprehensive assessment of 135 
the skeletal muscle phenotype in HFpEF, by applying in vitro, in situ, and in silico 136 
approaches to a validated obese cardiometabolic rat model, where ex vivo magnetic 137 
resonance imaging was used to characterise the degree of cardiac remodelling. 138 
Specifically, using hindlimb (soleus/EDL) and respiratory (diaphragm) muscle, we 139 
performed global and local fibre-type specific phenotyping of cross-sectional area, 140 
isoform, and capillarity alongside estimated muscle PO2. In parallel, we also directly 141 
assessed key functional measures during rest and contractions, including hindlimb 142 
blood flow as well as neural- and direct-muscle stimulated contractile mechanics. We 143 
reasoned a better understanding of the skeletal muscle phenotype in HFpEF across 144 
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multiple-system levels would provide important insights for better understanding the 145 
pathophysiology of exercise intolerance in this disease and help direct future patient 146 
experiments and therapeutic development in this field.   147 
 148 
  149 
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Methods  150 
Ethical approval  151 
All procedures and experiments were performed in accordance with the UK Scientific 152 
Procedures (Animals) Act 1986 and local approval was given by the University of 153 
Leeds Animal Welfare and Ethical Review Committee. All work conforms to the ethical 154 
requirements outlined by The Journal of Physiology (Grundy, 2015). 155 
 156 
Animals  157 
20-week-old male obese (n=8) and lean (n=8) diabetic Zucker fatty/spontaneously 158 
hypertensive heart failure F1 hybrid (ZSF1) rats (Charles River Laboratories) were 159 
used in this study. While both lean and obese ZSF1 rats inherit the hypertension gene, 160 
only the obese ZSF1 rats inherit a mutation in the leptin receptor gene 161 
(LeprfaLeprcp/Crl) that drives weight gain and metabolic impairments associated with 162 
typical signs of HFpEF developing as early as 10 weeks of age (Schauer et al., 2020) 163 
and well established after 20 weeks (Leite et al., 2015; Franssen et al., 2016; van Dijk 164 
et al., 2016; Bowen et al., 2017b). Lean ZSF1 rats served as controls. All rats were 165 
maintained in a 12-hour light/ dark cycle, with standard chow diets (RM1 chow, SDS) 166 
and water provided ad libitum.  167 
 168 
Cardiometabolic function  169 
Cardiometabolic impairments were confirmed by measures of body mass, mean 170 
arterial pressure (via an implanted carotid catheter (PP10)) with a blood pressure 171 
transducer (BP transducer, AD Instruments, UK) and blood glucose levels (via a 172 
commercial blood glucose meter (FreeStyle Mini Meter), while hearts were perfused 173 
and immersion fixed ex vivo using low osmolality Karnovsky’s fixative and 174 
subsequently imaged using a diffusion-weighted fast spin echo sequence at a 175 
resolution of 120 μm isotropic for cardiac phenotyping (Teh et al., 2016). These data 176 
were used to calculate mean thicknesses of the left and right ventricular free walls and 177 
the septum, for tissue located in the middle third of the distance between the base and 178 
apex of the appropriate ventricular cavity. Myocyte helix angles (quantifying myocyte 179 
inclination with respect to the short axis of the heart) were extracted from regions in 180 
the left and right ventricular free walls and the septum as previously described (Benson 181 
et al., 2011); myocyte disarray in these regions was quantified using the R2 of a 5th 182 
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order polynomial fit to the helix angles plotted as a function of transmural distance 183 
(Benson et al., 2008). All DT-MRI analyses were carried out using in-house software.  184 
 185 
In situ muscle performance and femoral artery blood flow   186 
In situ measurements of muscle function and blood flow were made under surgical 187 
anaesthesia, which was induced with isoflurane (4 % in 100 % oxygen) and maintained 188 
throughout experiments by constant syringe pump infusion (30-35 mg kg-1 h-1) of 189 
Alfaxalone (Jurox, Crawley, UK) delivered via an implanted jugular vein catheter. In 190 
situ functional assessment of muscle performance was determined as previously 191 
described (Egginton & Hudlicka, 1999; Tickle et al., 2020). In brief, extensor digitorum 192 
longus (EDL) isometric twitch force was recorded via a lever arm force transducer 193 
(305B-LR: Aurora Scienctific, Aurora, ON, Canada) following surgical extirpation of 194 
the overlying synergist tibialis anterior muscles. Electrical stimulation of the EDL (0.3 195 
ms pulse width) was accomplished via electrodes placed adjacent to the popliteal 196 
nerve (Hudlická et al., 1977), with initial electrical pulses (1 Hz) delivered to determine 197 
optimal muscle length and supramaximal current delivery. Simultaneous 198 
measurement of bilateral blood flow was facilitated by placement of perivascular flow 199 
probes (0.7PSB; Transonic, Ithaca, NY, USA) on the proximal portion of the femoral 200 
artery, adjacent to the profunda femoris bifurcation (Tickle et al., 2020). Quantification 201 
of resting and end stimulation flows enabled determination of the functional 202 
hyperaemia recruited during stimulation. Blood flow data is provided (ml min-1) and 203 
after normalisation for blood pressure variation, vascular conductance (ml min-1 mm 204 
Hg-1). All data were recorded via PowerLab and LabChart software (AD Instruments, 205 
UK). 206 
 207 
EDL twitch and maximal tetanic force, as well as fatigue resistance was also assessed. 208 
Fatigue resistance was quantified by monitoring isometric force throughout a period of 209 
continuous 10 Hz stimulation for 3 min. A fatigue index (FI) was then calculated as: 210 
(end-stimulation twitch tension/peak twitch tension) x 100. An average of five 211 
consecutive twitches was used to quantify end stimulation and peak EDL tension. 212 
Differences in the magnitude of the absolute tetanic force generated between groups 213 
were taken into account by employing a second bout of fatigue stimulation, such that 214 
absolute forces in HFpEF were initially similar to those attained in controls (i.e., 215 
matched-initial force) (Ferreira et al., 2010). This protocol is relevant for clinical 216 
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translation of muscle fatigue, where daily tasks in patients are often dependent upon 217 
the absolute rather than relative force being sustained that may involve an increase in 218 
firing frequency of motor neurons to achieve task completion (Weavil et al., 2020). 219 
Thus, by adjusting the stimulation frequency in HFpEF rats to around 25 Hz, tetanic 220 
force was increased and matched to the level recorded in the lean group, with fatigue 221 
allowed to proceed over 3 minutes. In addition, tetanic force production was quantified 222 
by 200 Hz stimulation (200 ms duration) after a minimum of 10 minutes recovery from 223 
fatigue, as determined by restoration of pre-fatigue resting blood flow. All protocols 224 
were performed in the exactly same order for each rat, thus minimising any effects of 225 
methodological variation. Force is presented in absolute units (g) and normalized to 226 
wet-mass for specific force (g/mg).  227 
 228 
In vitro functional assessment 229 
Immediately following euthanasia, the soleus and diaphragm were excised and 230 
prepared in a Krebs-Henseleit solution (in mmol/L: 117 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 231 
KH2PO4, 24.8 NaHCO3, 2.5 CaCl2, 11.1 glucose; in mmol/L) at 4°C equilibrated with 232 
95 % O2 / 5 % CO2. For the soleus, silk sutures (4.0) attached to tendons at either end 233 
were used to suspend the muscle vertically in a buffer-filled organ bath between a 234 
hook and a length-controlled lever system (305C, Aurora Scientific, Aurora, Canada). 235 
In vitro field stimulation using platinum electrodes was provided via a high power 236 
bipolar stimulator (701C, Aurora Scientific) outputting supramaximal current (700 mA; 237 
1 s train duration; 0.25-ms pulse width). After optimal contractile length (L0) was 238 
determined, the muscle was thermoequilibrated in a Krebs-Henseleit solution for 15 239 
min at ~21°C. For the diaphragm, a bundle of muscle fascicles (~2-3 mm wide) was 240 
removed from the medial section of the left costal diaphragm leaving two ribs and a 241 
section of the central tendon intact. The muscle bundle was transferred to a flow-242 
through muscle chamber and anchored between a base and ergometer (series 300B-243 
LR, Aurora Scientific Inc.) and stimulated through parallel platinum electrodes using a 244 
stimulus isolation unit (0.2 ms pulse width; UISO model 236, Hugo Sachs Elektronik). 245 
After L0 was determined, the diaphragm bundle was thermoequilibrated in a Krebs-246 
Henseleit solution for at least 15 min at 37°C. Each muscle was circulated with 247 
oxygenated (95 % O2 / 5 % CO2) Krebs-Henseleit solution throughout each 248 




The soleus underwent two protocols: isometric force-frequency and isotonic force-251 
velocity. The force-frequency relationship was determined in response to pulses at 1, 252 
15, 30, 50, 80, 120 and 150 Hz, with 1 min of recovery between contractions. After a 253 
five minute period in which muscle length was measured using digital callipers, the 254 
soleus was subjected to a series of afterloaded-isotonic contractions to determine the 255 
force-velocity relationship, where the muscle was allowed to shorten against external 256 
loads (80 – ~5% of the maximal tetanic force; each separated by 1 min for the soleus 257 
or 5 min for the diaphragm) after being stimulated at 150 Hz for 300 ms. Shortening 258 
velocity was determined 10 ms after the first change in length and on the linear section 259 
of the transient (605A DMA software, Aurora Scientific). For the diaphragm, maximal 260 
isometric twitch and tetanic (250 ms train at 150 Hz), isotonic force-velocity (as above), 261 
and work-loop protocols were performed. Muscle performance assessed using the 262 
work loop technique included simulating performance in vivo, by subjecting the muscle 263 
to cyclical length changes and phasic stimulation (Josephson, 1985). A sinusoidal 264 
length change at a range of cycle frequencies (1 – 15 Hz) and strain amplitude of 265 
0.065 L0 was imposed on the muscle and, for each cycle frequency, the timing and 266 
duration of stimulation were optimised to maximise net work. Isometric tetanic 267 
contractions and cyclical contractions at 5 Hz were performed periodically to monitor 268 
any decline in the preparation, assessed by expressing isometric stress (isotonic 269 
contractions) and net work relative to maximal values. A linear decline in performance 270 
was assumed in correcting data for preparation decline. A period of 5 minutes was 271 
allowed following isotonic and work loop contractions for recovery. To assess the 272 
muscle’s ability to sustain work, a fatigue test was done by subjecting the muscle to a 273 
series of cyclical contractions (cycle frequency 2 Hz, strain amplitude 0.065 L0, phase 274 
-20 ms relative to peak length, 210 ms stimulation duration). Custom written software 275 
was used to control muscle length and stimulation and to acquire length and force data 276 
(CEC Testpoint version 7) via a D/A data acquisition card (DAS1802AO, Keithley 277 
Instruments). Data were acquired at a sample frequency of 10 kHz (isometric and 278 
isotonic) or 1000 x cycle frequency (work loops).  279 
 280 
At the end of each experiment, the muscle was blotted on paper tissue and wet mass 281 
recorded. Force (N) was normalised to muscle cross‐sectional area (CSA; cm2) after 282 
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dividing muscle mass (g) by the product of L0 (cm) and estimated muscle density (1.06 283 
g/cm3) to allow specific-force (i.e., stress) in N/cm2 to be calculated (Close, 1972). 284 
Shortening velocity was normalised to optimal muscle length (in L0/s), while power 285 
was calculated as the product of shortening velocity and force normalised to muscle 286 
mass (in W/kg). Twitch properties (i.e., peak force; time-to-peak tension, TPT; Half 287 
relaxation time, HRT) as well as maximal isometric tetanic force (i.e. 𝑃0) were 288 
calculated. A hyperbolic-linear relationship was fit to the force-velocity data to 289 
determine the maximum shortening velocity (𝑉𝑚𝑎𝑥), peak isotonic power (?̇?𝑚𝑎𝑥), and 290 
the power ratio (?̇?𝑚𝑎𝑥/(𝑃0 × 𝑉𝑚𝑎𝑥); a measure of the curvature of the force-velocity 291 
relationship (Marsh and Bennet, 1986)). 292 
 293 
Histological analysis  294 
Mid-portions of the right costal diaphragm and left soleus muscle were mounted in 295 
OCT embedding medium (Thermo Scientific, Loughborough, UK), frozen in liquid 296 
nitrogen-cooled isopentane and stored at -80°C. To identify muscle fibre types, 297 
sections (10 μm thick) were fixed for 2 minutes in 2 % paraformaldehyde, washed in 298 
phosphate-buffered saline (PBS; P4417, Sigma-Aldrich, St Louis, MO) and blocked 299 
for 10 minutes in 1 % BSA (A6003, Sigma-Aldrich, St Louis, MO). Sections were then 300 
incubated for 60 min with monoclonal-myosin heavy chain (MHC) antibodies BA-D5 301 
(IgG2B, 1:1000) and SC-71 (IgG1, 1:500) for Type I (oxidative) and Type IIa (fast 302 
oxidative, glycolytic) fibres, respectively (Developmental Studies Hybridoma Bank, 303 
Iowa City, IA, USA). The remaining unstained fibres were considered to be Type IIb/IIx, 304 
as previously described (Kissane et al., 2018). After washing in PBS, sections were 305 
incubated for 60 min with secondary antibodies Alexa Fluor 555 (conjugated goat anti-306 
mouse IgG, 1:1000, A-21422, Thermo Fisher Scientific, Waltham, MA) and Alexa 307 
Fluor 488 (conjugated rabbit anti-mouse IgG, 1:1000, A11059, Thermo Fisher 308 
Scientific, Waltham, MA). Muscle fibre boundaries were labelled with a rabbit anti-309 
laminin antibody (1:200; L9393, Sigma-Aldrich, St Louis, MO), an extracellular matrix 310 
glycoprotein within the basement membrane. Finally, capillaries were stained with a 311 
carbohydrate-binding protein (lectin) specific to rodent endothelial cells, Griffonia 312 
simplicifolia lectin I (GSL I; Vector Labs, Peterborough, UK; FL-1101). Slides were 313 
then imaged at magnifications of x10 (soleus) and x20 (diaphragm) using the Nikon 314 
Eclipse E600 (Nikon, Tokyo, Japan) optical microscope attached to a digital camera 315 
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(QIMAGING, MicroPublisher™ 5.0 RTV, Surrey, BC, Canada). Subsequent image 316 
analysis with the stand-alone graphic user interface, DTect, and a MATLAB-based 317 
oxygen transport modeller (The MathWorks, Cambridge, United Kingdom; (Al-318 
Shammari et al., 2019)) enabled calculation of fibre-type-specific cross-sectional area 319 
(FCSA), capillary-to-fibre ratio (C:F), capillary density (CD), capillary domain area 320 
(CDA), local capillary-to-fibre ratio (LCFR), local capillary density (LCD) and estimated 321 
tissue oxygen tension (PO2). Multiple regions of interest of each muscle (3 for the 322 
diaphragm and 2 for the soleus) were randomly assigned to establish an unbiased 323 
counting frame, taking into account the regional heterogeneity across muscles 324 
(Kissane et al., 2018). In general, each region of interest of the soleus muscle 325 
contained ~ 155 fibres and the diaphragm ~ 70 fibres.    326 
 327 
In silico muscle PO2 modelling  328 
Our model applied mathematical and computational frameworks to generate 329 
theoretical predications of the cross-sectional distribution of PO2 in the soleus and 330 
diaphragm using a custom MATLAB ‘oxygen transport modeller’, as previously 331 
described in detail elsewhere (Al-Shammari et al., 2019). Briefly, using digitised 332 
images of muscle cryosections, individual fibre boundaries were identified, a 333 
phenotype assigned, and capillary locations defined.  A computational framework was 334 
then established allowing a mathematical mesh of equations to be superimposed on 335 
realistic geometry. Tissue PO2 measurements were then derived from incorporating 336 
estimates (applied similarly in each group) of capillary radius (1.8–2.5 × 10−4 cm), 337 
muscle oxygen consumption (15.7 × 10−5 ml O2 ml−1 s−1), myoglobin concentration 338 
(10.2 × 10−3 ml O2 ml−1), O2 solubility (3.89 × 10−5 ml O2 ml−1 mmHg−1) and diffusivity 339 
(1.73 × 10−7 cm2 s−1), as detailed elsewhere (Al-Shammari et al., 2019) with direct 340 
measurement of these specific parameters beyond the scope of the present study 341 
(Tickle et al., 2020). As such, any differences between groups in terms of 342 
mitochondrial function (or other assumed variables) were not accounted for in our 343 
model. Relevant biophysical parameters affecting O2 diffusion from reputable sources 344 
were used in the mathematical model to generate predictions of the cross-sectional 345 
distribution of PO2 in a muscle biopsy under simulated resting and maximal oxygen 346 
consumption conditions. As with all biological models, inherent limitations prevent full 347 
characterisation of the wide myriad of interacting variables, however relative changes 348 
within a given tissue were the key output and are likely robust. In line with former 349 
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studies (Al-Shammari et al., 2019), compensation for differences in many parameters, 350 
e.g. myoglobin saturation, have relatively small effects on the documented outcomes 351 
due to the dominant effect of capillary supply and fibre size on peripheral O2 transport.   352 
 353 
Statistical analyses 354 
Following appropriate checks of normality, between‐group differences were assessed 355 
by unpaired two-tailed Student t-tests. Contractile relationships were analysed as 2-356 
way repeated measures ANOVA followed by Bonferroni post hoc test, where 357 
appropriate. Analyses were performed in GraphPad Prism v.8. Data are presented as 358 
mean±SD, and the level of significance was set at P<0.05 for all analyses.      359 




Cardio-metabolic phenotype  362 
As previously noted (Leite et al., 2015; Franssen et al., 2016; van Dijk et al., 2016; 363 
Bowen et al., 2017b) (Schauer et al., 2020), by 20 weeks of age obese-ZSF1 rats have 364 
developed typical metabolic signs associated with HFpEF including obesity (P<0.001; 365 
Figure 1A), hyperglycaemia (P<0.001; Figure 1B) and hypertension (P=0.012; Figure 366 
1C). In addition, obese rats developed cardiac remodelling typically associated with 367 
HFpEF that included RV hypertrophy (P=0.034; Figure 1D), although LV and septal 368 
wall enlargement was not observed at this time point (P=0.719; Figure 1E and 369 
P=0.849; Figure 1F). Further, myocyte organisation/disarray was also not significantly 370 
deteriorated (RV: P=0.971, LV: P=0.13, septum: P=0.064: Figure 1G-H).    371 
 372 
Histological and in vitro functional characteristics of the soleus muscle 373 
As shown in representative muscle sections (Figure 2A-B), soleus from obese-HFpEF 374 
rats demonstrated clear atrophy with a 26% lower wet-mass (P<0.001; Figure 2C) and 375 
a 23% lower CSA of both Type I (P<0.001) and Type IIa fibres (P=0.001; Figure 2D) 376 
when compared to lean controls. No Type IIx/b fibres were detected in either group. 377 
HFpEF rats also had a lower numerical and areal composition of Type I fibres 378 
(P=0.002; Figure 2E and P=0.043; Figure 2F, respectively), whereas these were 379 
higher in Type IIa fibres (P=0.002 and P=005, respectively). In addition, HFpEF rats 380 
had a lower C:F (P=0.002; Figure 2G) but a higher CD, indicating atrophy proceeded 381 
at a greater rate than capillary loss (P=0.027; Figure 2H), while CDA did not differ 382 
significantly (P=0.059; Figure 2I). Analyses of local capillary distribution revealed that 383 
HFpEF rats had lower LCFR in Type I fibres (P=0.011), and while a similar trend was 384 
found in Type IIa fibres this did not reach significance (P=0.154; Figure 2J). In contrast, 385 
LCD in Type I fibres was higher in HFpEF rats (P=0.029), and again while a similar 386 
trend was found in Type IIa fibres this did not reach significance (P=0.196; Figure 2K). 387 
To understand whether HFpEF influenced muscle PO2, we simulated muscle oxygen 388 
tension (PO2) under resting (Figure 3A-C) and maximal demand (Figure 3D-F). No 389 
differences between groups were found after calculation of muscle oxygenation at 390 
either rest (Type I fibres: P=0.099, Type IIa: P=0.167, all fibres: P=0.102; Figure 3C) 391 
or maximal rate of oxygen consumption (Type I: P=0.109, Type IIa: P=0.177, all fibres: 392 




The soleus generated lower absolute twitch and maximal forces in HFpEF compared 395 
to control rats (P<0.001; Figure 4A and P=0.005; Figure 4B, respectively), consistent 396 
with muscle atrophy, although after adjustment for muscle cross-sectional area there 397 
was no difference between groups in specific forces (P=0.056, Figure 4C; and 398 
P=0.557, Figure 4D, respectively). Similarly, twitch characteristics of half relaxation 399 
time (P=0.603; Figure 4E) and time to peak tension (P=0.474; Figure 4F) remained 400 
unchanged, as did the maximal twitch:tetanus ratio between control and HFpEF 401 
(0.16±0.03 vs. 0.14±0.02; P=0.140). However, HFpEF rats demonstrated impairments 402 
to both shortening velocity (range 10-17 %) and mechanical power (range 14-22 %) 403 
when measured across various percentages of their maximal force (P<0.05; Figure 404 
4G-H), suggesting HFpEF reduces intrinsic soleus contractile function related to 405 
muscle shortening rather than specific force. Interestingly, however, while Vmax was 406 
not different between groups (1.16±0.52 vs. 0.88±0.33 L0/s; P=0.307), there was a 407 
tendency for the force-velocity curvature to be 25% greater in HFpEF compared to 408 
controls (i.e., a lower power ratio: 0.06±0.02 vs. 0.08±0.02; P=0.086).       409 
 410 
In situ muscle function and femoral artery blood flow 411 
EDL muscle wet-mass was 26% lower in HFpEF rats (P<0.001; Figure 5A). This 412 
corresponded to lower absolute twitch and maximal forces of 27% and 33%, 413 
respectively (P=0.016; Figure 5B and P=0.030; Figure 5C, respectively). When 414 
normalised to muscle mass, twitch and maximal specific forces were not different 415 
between groups (P=0.968; Figure 5D and P=0.675; Figure 5E, respectively), while 416 
relative fatigability was unaffected (P=0.325; Figure 5F). However, HFpEF rats tended 417 
to be around 26% more fatigable during the force-matched protocol (P=0.079; Figure 418 
5G). While HFpEF rats had higher levels of resting femoral artery blood flow (P=0.039; 419 
Figure 5H), they showed a severely blunted hyperaemic response of 73% increase in 420 
blood flow during repeated contractions (P=0.012; Figure 5I). Similarly, impairments 421 
in the hyperaemia calculated using vascular conductance was found in HFpEF 422 
(P=0.004; Figure 5J). Overall, this suggests that while obese-HFpEF does not induce 423 
muscle dysfunction related to neuromuscular transmission failure, a severe decrement 424 




Histological and functional characteristics of the diaphragm  427 
Representative diaphragm sections from control and HFpEF rats are presented in 428 
Figure 6A-B. Average FCSA was similar between groups (P=0.609; Figure 6C), 429 
however compared to lean controls HFpEF increased FCSA in both type I and type 430 
IIa fibres by 46 % (P<0.001) and 26 % (P=0.005), respectively (Figure 6C), but 431 
reduced type IIb/IIx FCSA by 22 % (P=0.004). Additionally, HFpEF rats had a higher 432 
numerical percentage of type I fibres (P=0.003; Figure 6D) and a higher area 433 
percentage of type I fibres (P<0.001; Figure 6E).  434 
 435 
Global and local alterations were also observed in capillary distribution, with C:F and 436 
CD increased in HFpEF rats (P=0.015; Figure 6F and p=0.049; Figure 6G, 437 
respectively) but CDA did not differ significantly (P=0.362; Figure 6H). HFpEF rats had 438 
increased LCFR in Type I (P<0.001) and Type IIa fibres (P<0.001), whereas this was 439 
reduced in type IIb/IIx fibres (P=0.040; Figure 6I). In contrast, LCD was higher in 440 
HFpEF for Type IIb/IIx fibres (P=0.042), with no changes in Type I (P=0.152) and Type 441 
IIa fibres (P=0.128; Figure 6J). We next estimated diaphragm PO2 levels (Fig. 7A-B) 442 
and found HFpEF elevated resting muscle oxygen tension (Type I fibres: P=0.043, 443 
Type IIa: P=0.019, Type IIb/IIx: P=0.006, all fibres: p=0.009; Figure 7C) and at 444 
maximal metabolic rates (Type I: P=0.045, Type IIa: p=0.018, Type IIb/IIx: p=0.004, 445 
all fibres: P=0.006; Figure 7F), indicating improved muscle oxygenation in obese-446 
HFpEF.  447 
 448 
Isometric twitch and maximal tetanic stress of the diaphragm were similar between 449 
groups (P=0.254; Figure 8A and P=0.225; Figure 8B, respectively), however, analysis 450 
of twitch kinetics demonstrated that HFpEF rats had a slower time to peak tension 451 
(P=0.006; Figure 8C) while half relaxation time remained unchanged (P=0.170; Figure 452 
8D) as did the maximal twitch:tetanus ratio between control and HFpEF (0.31±0.06 453 
vs. 0.32±0.05; P=0.630). Similarly, there were no differences in isotonic properties as 454 
assessed by maximal shortening velocity or maximal isotonic power between groups 455 
(P=0.756; Figure 8E and P=0.670; Figure 8F), with the power ratio also not different 456 
between groups (0.11±0.01 vs. 0.11±0.01; P=0.253). During the cyclical contractions, 457 
there were no differences in the net power recorded at any given frequency and no 458 
difference in the cycle frequency that yielded maximum net power (i.e. 5 Hz for both 459 
groups) (all P>0.05; Figure 8G). However, during repeated cyclical contractions the 460 
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ability of the diaphragm to sustain work and power relative to the unfatigued state was 461 
reduced in HFpEF compared to controls (P=0.001) and this occurred after relatively 462 
few cycles of work (cycles 6-12; P<0.05; Figure 8H). 463 
  464 
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Discussion  465 
This study has identified novel skeletal muscle impairments in obese-HFpEF that likely 466 
predispose towards the pathophysiology of exercise intolerance. The main findings 467 
from this study are:   468 
1) Limb muscle weakness was closely associated with fibre atrophy in HFpEF, but 469 
isometric contractile properties were not impaired under neural- or direct-muscle 470 
assessments, indicating preserved isometric neuromuscular function. 471 
2) In contrast, limb isotonic muscle properties including shortening velocity and 472 
mechanical power were impaired in HFpEF. 473 
3) An abnormal leg blood flow response to contractions alongside fibre-type specific 474 
structural capillary loss were found in HFpEF, indicating perfusive O2 transport 475 
limitations.  476 
4) Significant remodelling of the diaphragm occurred in HFpEF including divergent 477 
fibre-type hypertrophy/atrophy, higher capillarity/PO2, and a Type I fibre-type shift, with 478 
preserved muscle mechanics.   479 
 480 
Impact of HFpEF on limb muscle function  481 
A reduction in skeletal muscle mass in patients with HFpEF is strongly associated with 482 
reduced muscle strength and poor quality of life (Bekfani et al., 2016). Muscle 483 
weakness is generally underpinned by either a reduction in muscle mass (i.e., atrophy) 484 
and/or intrinsic contractile dysfunction. In this study, we used in vitro (i.e. direct-485 
muscle) and in situ (i.e., peripheral nerve) stimulation approaches to assess isometric 486 
contractile properties in limb muscle. This allowed various sites in the muscle 487 
contractile process to be evaluated for dysfunction in HFpEF, including neuromuscular 488 
transmission and excitation-contraction coupling. Consistent with previous data where 489 
absolute maximal soleus force was reduced by ~20 % in HFpEF rats vs. controls 490 
(Bowen et al., 2018; Schauer et al., 2020), we observed that absolute twitch and 491 
maximal forces in both the soleus and EDL were lower in HFpEF rats. However, limb 492 
muscle weakness was closely associated with fibre atrophy as, after normalising for 493 
muscle mass, specific forces were not different between groups independent of 494 
whether neural and blood supply remained intact. This is important, as it indicates that 495 
neuromuscular transmission and excitation-contraction coupling is likely preserved 496 




However, most daily activities require the muscle to shorten against different loads to 499 
generate mechanical power and thus perform work. Therefore, assessment of muscle 500 
isotonic properties such as shortening velocity and power, which remained undefined 501 
in HFpEF, provide a more relevant assessment in relation to daily patient activities. 502 
Here, we observed that HFpEF rats had impairments to both shortening velocity and 503 
mechanical power in the soleus. This functional loss in HFpEF cannot be explained 504 
by a simple shift towards more Type I fibres (i.e. typically associated with slower 505 
shortening velocities where myosin heavy chain isoform is a key determinant (Bottinelli 506 
et al., 1991)), as we observed a higher proportion of Type IIa fibres in HFpEF. As such, 507 
while this rules out a Type I fibre-type shift as a potential mechanism underlying the 508 
slower shortening velocities observed in HFpEF, shortening velocity is also thought to 509 
be limited by the rate of ADP dissociation from actomyosin (Nyitrai et al., 2006). Thus, 510 
our data suggest obese-HFpEF rats develop slowed rates of cross-bridge detachment 511 
through impaired ADP release, potentially due to post-translational modifications of 512 
myosin related to oxidative stress or glycation, as previously reported in HFrEF 513 
(Coirault et al., 2007) and ageing (Ramamurthy et al., 1999). In further support, slowed 514 
cross-bridge kinetics have previously been reported in Type I and IIa fibres of vastus 515 
lateralis biopsies from patients with HFrEF (Miller et al., 2010), although other 516 
mechanisms such as impaired sarcoplasmic reticulum calcium pumping cannot be 517 
ruled out. Interestingly, we also found a tendency in the soleus for the curvature of the 518 
force-velocity relationship to be greater in HFpEF compared to controls (i.e., where 519 
curvature is the inverse of the a/𝑃0 ratio in the Hill equation), which is in line with 520 
previous studies highlighting significant power loss during fatiguing exercise when 521 
curvature is greater (or a/𝑃0 lower) (Jones, 2010). As such, a greater curvature of the 522 
force-velocity relationship may be another potential mechanism contributing to the loss 523 
of power observed in HFpEF. Overall, therefore, the significant loss of absolute limb 524 
force associated with muscle atrophy in HFpEF alongside intrinsic impairments related 525 
to lower shortening velocity and increased curvature would be predicted to severely 526 
reduce mechanical power and thus predispose towards exercise intolerance.   527 
 528 
Impact of HFpEF on limb skeletal muscle morphology  529 
Despite skeletal muscle morphological alterations being well investigated in HFrEF 530 
(Kennel et al., 2015), little information is available on HFpEF from either animal or 531 
patient studies. Previous data from patients with HFpEF indicated the vastus lateralis 532 
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Type I to Type II fibre-type shift and a lower global C:F ratio, which is associated with 533 
reduced V̇O2peak (Kitzman et al., 2014). Animal models (hypertensive or 534 
cardiometabolic) have shown in the soleus/EDL a significant fibre atrophy and a lower 535 
global C:F ratio (Bowen et al., 2015; Bowen et al., 2017b; Bowen et al., 2018; Schauer 536 
et al., 2020). Consistent with this, in the present study we found soleus muscle in 537 
HFpEF rats exhibited a fibre atrophy of 24% and a Type IIa fibre-type shift alongside 538 
a lower global C:F ratio of 17%. In contrast, however, we also provide new evidence 539 
that capillary density (CD) in the soleus was higher in HFpEF rats by 15% vs controls, 540 
and by using novel local measures of capillarity (i.e., LCRF, LCD), we identified that 541 
while a similar trend was found in both fibre types, only Type I reached statistical 542 
significance. These additional local indices allowed us to further conclude that the 543 
lower C:F ratio observed in HFpEF was the result of a greater contribution from Type 544 
I fibres (i.e., LCRF), suggesting slow- rather than fast-twitch fibres tended to be more 545 
susceptible to microvascular alterations in this disease. However, the capillary supply 546 
per cross sectional area of Type I fibres (LCD) was in fact higher in HFpEF muscle. 547 
These global and local measures of capillarity where C:F was lower but CD higher in 548 
HFpEF are likely explained by the observed fibre atrophy, as CD is highly dependent 549 
upon fibre size (Egginton, 2011). This indicates that the degree of fibre atrophy 550 
exceeded the rate of capillary loss in HFpEF, thus increasing the CD, which has been 551 
suggested as an adaptive process to reduce diffusion distances across muscle fibres 552 
(Al-Shammari et al., 2019), helping to discriminate structural from functional 553 
consequences of microvascular remodelling. A reduced distance for oxygen diffusion 554 
could be the result of an adaptation to the lower blood flow, as we observed. In HFpEF, 555 
this may also be a compensatory mechanism to preserve O2 flux from capillary to 556 
myocyte and thus maintain a better PO2 status across the muscle, not only in the face 557 
of capillary loss but also in response to the reported deficits in mitochondrial O2 558 
utilisation (Bowen et al., 2015; Molina et al., 2016; Bowen et al., 2017b).  559 
 560 
In this regard, data collected from patients with HFpEF have identified clear 561 
impairments in the ability to widen arterial-venous O2 content (ΔAVO2) and augment 562 
peripheral oxygen extraction during exercise compared to HFrEF or controls (Bhella 563 
et al., 2011a; Haykowsky et al., 2011; Dhakal et al., 2015; Houstis et al., 2018; Zamani 564 
et al., 2020). It remains unclear whether the capillary loss we observed contributes to 565 
abnormal skeletal muscle O2 extraction at peak exercise in HFpEF, with a peripheral 566 
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O2 diffusive limitation postulated as a major mechanism underpinning exercise 567 
intolerance in HFpEF (Dhakal et al., 2015; Houstis et al., 2018). To expand current 568 
knowledge (Dhakal et al., 2015; Houstis et al., 2018; Zamani et al., 2020), we therefore 569 
used in silico modelling to provide the first fibre-type specific estimates of 570 
microvascular contribution to muscle oxygenation in HFpEF. We found muscle PO2 571 
was similar between HFpEF and control during simulated rest and at maximal 572 
exercise, which indicates adequate oxygenation is maintained in HFpEF with no 573 
evidence for enhanced tissue hypoxia. A recent patient study using forearm exercise 574 
found estimated peripheral O2 diffusion was not different between HFpEF and controls 575 
(Zamani et al., 2020), but this contrasts with previous cycling studies where O2 576 
diffusion was significantly lower based on systemic hemodynamic, blood gas and 577 
pulmonary gas exchange measurements (Dhakal et al., 2015; Houstis et al., 2018). It 578 
should be noted that these patient studies did not measure leg/muscle ΔAVO2, fibre 579 
size, capillarity, or microvascular distribution, which can all influence peripheral O2 580 
diffusion. While the current data do not allow us to directly confirm whether O2 diffusion 581 
was impaired in obese-HFpEF, our data suggest that fibre morphology and capillary 582 
distribution are unlikely to contribute to O2 diffusive limitations.  583 
 584 
Interestingly, and in contrast to HFrEF or controls, patients with HFpEF are unable to 585 
lower venous PO2 during exercise and therefore demonstrate a blunted peripheral O2 586 
extraction response (Dhakal et al., 2015; Houstis et al., 2018; Poole et al., 2018; 587 
Zamani et al., 2020). The extent of this impaired muscle O2 extraction in HFpEF is 588 
likely explained, at least in part, by the significant mitochondrial abnormalities reported 589 
in patients with HFpEF (Molina et al., 2016). In our study, estimated muscle PO2 in 590 
HFpEF was not lower than controls at simulated maximal exercise, and while not 591 
discounting the potential for a muscle O2 diffusion limitation (Poole et al., 2018), this 592 
is consistent with maintenance of a high muscle oxygenation across the muscle in 593 
HFpEF to support more optimally functioning mitochondria (Al-Shammari et al., 2019). 594 
Clearly, more studies are warranted to clarify the role of limitations to muscle O2 595 
diffusion in HFpEF, however our present data of a reduced leg blood flow (see below) 596 
implicate a perfusive O2 delivery limitation as one key mechanism that could potentially 597 




Impaired muscle blood flow response in HFpEF  600 
Up until now, direct measures of leg (muscle) arterial blood flow had not been 601 
assessed in HFpEF, limiting mechanistic understanding. In the present study, using 602 
perivascular flow probes (the gold-standard for measuring volumetric blood flow in 603 
animal studies), we directly demonstrated that the functional hyperaemic response to 604 
contractions was blunted in HFpEF rats. These data support the concept that the 605 
peripheral response to exercise is impaired in HFpEF (Houstis et al., 2018), and are 606 
consistent with non-invasive measurements in patients with HFpEF during knee-607 
extensor exercise where impaired leg blood flow and vascular conductance occurred 608 
independently of limitations to heart rate, stroke volume and cardiac output (Lee et al., 609 
2016b; Weavil et al., 2020) but contrast with recent isometric forearm data which did 610 
not find any change (Zamani et al., 2020). However, some (Lee et al., 2016b; 611 
Maréchaux et al., 2016; Kishimoto et al., 2017; Weavil et al., 2020) but not others 612 
(Hundley et al., 2007; Haykowsky et al., 2013; Lee et al., 2016a; Zamani et al., 2020) 613 
report an abnormal blood flood response to exercise in HFpEF patients when 614 
compared to controls, which is probably related to differences in the muscle studied, 615 
non-invasive and different measurements techniques, and patient heterogeneity. 616 
Overall, our data supports the potential for perfusive, feed-artery O2 transport 617 
limitations in HFpEF, which likely contributes to exercise intolerance in this disease 618 
(Poole et al., 2018; Weavil et al., 2020).  619 
 620 
Although the mechanisms underlying abnormal limb blood flow response to exercise 621 
in HFpEF remain unclear, endothelial function is impaired (Schmederer et al., 2018) 622 
and postulated as a central mechanism underlying disease progression (Paulus & 623 
Tschöpe, 2013; Gevaert et al., 2017; Schmederer et al., 2018). Beyond this, upstream 624 
central impairments related to cardiac output likely play a major role (Wolsk et al., 625 
2019). While the functional significance of an impairment to limb blood flow during 626 
exercise in HFpEF is not known, it may exacerbate the degree of muscle fatigue 627 
experienced and limit daily activities performed by patients where the ability to 628 
repeatedly sustain absolute forces rather than relative forces becomes crucial, as 629 
recently demonstrated in patients with HFpEF (Weavil et al., 2020). This is supported 630 
by our employed matched-initial force fatigue protocol, where HFpEF rats showed a 631 
trend to be 26% more fatigable than controls. These data provide important clinical 632 
relevance, as patients with muscle weakness such as HFpEF are often required to 633 
23 
 
increase motor firing frequencies to perform certain daily activities that induce early 634 
fatigue (Ferreira et al., 2010; Weavil et al., 2020), although it is important to note this 635 
may not necessarily reflect direct differences in relation to muscle fatigue properties. 636 
Our data therefore indicates that skeletal muscle arterial blood delivery is potentially 637 
constrained during exercise in HFpEF. As such, at least in the context of this animal 638 
model and in support of recent patient findings (Weavil et al., 2020), a perfusive O2 639 
delivery limitation could play a key role limiting O2 extraction and thus exacerbating 640 
exercise intolerance in obese-HFpEF (Poole et al., 2018; Zamani et al., 2020). 641 
Interestingly, a lower leg blood flow during contractions coupled with a higher muscle 642 
CD in obese-HFpEF could result in an increased red blood cell transit time to mediate 643 
a greater O2 extraction. However, this may not transpire in HFpEF due to the 644 
significant mitochondrial abnormalities developed in patients (Molina et al., 2016), thus 645 
preventing any significant widening of the ΔAVO2. 646 
 647 
Impact of HFpEF on diaphragm remodelling and muscle mechanics  648 
Inspiratory (i.e. diaphragm) muscle weakness is evident and closely associated with 649 
symptoms of dyspnoea and poor prognosis in patients with HFpEF (Lavietes et al., 650 
2004; Hamazaki et al., 2020). Multiple alterations to the diaphragm have been reported 651 
in HFpEF, including in vitro muscle weakness and fatigue alongside a Type II-to-I fibre 652 
type shift, fibre atrophy, and impaired in situ mitochondrial respiration in a hypertensive 653 
rat model (Bowen et al., 2015). In contrast, we show remodelling of the HFpEF 654 
diaphragm that is reminiscent of exercise-training including fibre hypertrophy, 655 
increased mitochondrial content, and preserved fatigue-resistance, although evidence 656 
for mitochondrial uncoupling and a mild isometric contractile dysfunction have been 657 
noted (Bowen et al., 2017b). The disparity in findings between models is likely 658 
explained by the co-morbidity of obesity and its associated chronic respiratory loading, 659 
which can act as a training stimulus to increase fibre size, mitochondrial 660 
function/content, and fatigue-resistance (Farkas et al., 1994; Powers et al., 1996). 661 
Whether similar findings are observed between obese vs. lean patients with HFpEF 662 
remains unknown.  663 
 664 
Given that approximately 80% of HFpEF patients are obese (Shah et al., 2016) and a 665 
recent distinct obese-HFpEF phenotype has been established (Obokata et al., 2017), 666 
the present study contributes novel and highly-relevant data in relation to diaphragm 667 
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plasticity. Until now, only limited data have been available with respect to fibre-type 668 
structure, isoform, and microvasculature of the diaphragm in HFpEF (Bowen et al., 669 
2015; Bowen et al., 2017b). In the present study, we identified three major fibre types 670 
(Type I, IIa and IIb/IIx) to provide new evidence of a divergent hypertrophy/atrophy 671 
fibre remodelling in obese-HFpEF alongside increased indices of global and local 672 
capillarity (i.e., C:F and CD), and estimated levels of fibre oxygenation at rest and 673 
maximal exercise. Specifically, compared to controls, obese-HFpEF rats had 674 
increased Type I/IIa FCSA, and reduced Type IIb/IIx FCSA, indicating compensatory 675 
adaptations in slow-twitch fibres. This observation corresponds to the morphometric 676 
alterations following unilateral denervation of rat diaphragm muscle, where 677 
hypertrophy in Type I fibres but atrophy in Type IIb/IIx fibres occurred (Aravamudan et 678 
al., 2006). In support, albeit in the limb gastrocnemius, denervation has been 679 
demonstrated to induce fibre atrophy at a relatively higher rate than capillary 680 
rarefaction to mediate a higher CD (Paudyal et al., 2018), which is in line with our 681 
findings from the diaphragm in HFpEF. Nevertheless, it remains unclear whether 682 
obese-HFpEF induces partial diaphragm muscle denervation in fast-twitch Type IIb/x 683 
as reported in other conditions such as aging (Elliott et al., 2016).  684 
 685 
Overall the obese-HFpEF diaphragm demonstrates improved indices of oxygen 686 
transport (increased capillarity and PO2 distribution) that likely supports the observed 687 
shift towards an oxidative phenotype (i.e., higher proportion of Type I fibres, 688 
mitochondrial content, and antioxidative enzyme capacity (Bowen et al., 2015; Bowen 689 
et al., 2017b). This suggests that any functional diaphragm impairments developed in 690 
obese-HFpEF were likely offset by morphological adaptations. To decipher this 691 
potential trade-off, we performed in vitro isometric, isotonic and cyclical contractions 692 
on the diaphragm in one of the most detailed functional assessments in HFpEF to 693 
date. Our data indicate that impaired muscle mechanics and intrinsic diaphragm 694 
dysfunction generally do not develop early in the time course of obese-HFpEF (~20 695 
weeks), with only a mild increase found compared to controls in terms of fatigability. 696 
Again, these data conflict with previous experimental data where a significant 697 
reduction in diaphragm force during repeated isometric contractions was measured in 698 
rats with more advanced hypertensive-induced HFpEF (Bowen et al., 2015). In the 699 
present study we also simulated in vivo respiratory muscle mechanics, by applying 700 
cyclical length changes and phasic stimulation to the muscle to generate cycles of 701 
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work, using the in vitro work-loop technique (Josephson, 1985). Similar to our isolated 702 
isometric and isotonic measures, net power output during unfatigued cyclical 703 
contractions in obese-HFpEF was unaffected in the diaphragm, but we did observe a 704 
mild increase in fatigue during repeated cyclical contractions. Collectively, these data 705 
suggest respiratory muscle dysfunction is unlikely a key player in the pathogenesis of 706 
exercise intolerance in obese-HFpEF, at least during early disease progression. 707 
 708 
Study Limitations  709 
We did not use echocardiography or invasive haemodynamics to quantify the extent 710 
of left ventricular diastolic function and ejection fraction. However, this rat model has 711 
been validated and consistently develops key features of HFpEF as early as 10-15 712 
weeks of age (Schauer et al., 2020), including impaired diastolic function, preserved 713 
ejection fraction, myocardial remodelling, and exercise intolerance (Hamdani et al., 714 
2013; Leite et al., 2015; Franssen et al., 2016; van Dijk et al., 2016; Bowen et al., 715 
2017b). Instead, we used MRI to confirm the presence of cardiac remodelling which 716 
occurred in the RV and this is known to be closely associated with HFpEF 717 
development in obese patients (Obokata et al., 2017) and one of the strongest 718 
predictors of poor prognosis (Burke et al., 2014). We also compared groups at a 719 
relatively early time point in the progression of HFpEF, which may limit translation of 720 
our findings to more advanced stages of the disease. In addition, our experiments 721 
were performed in male rats only such that it remains unclear whether similar findings 722 
are observed in females, although a recent study confirmed a similar time course in 723 
disease progression is observed in females, supporting translation (Schauer et al., 724 
2020). Further, while differences in physical activity levels between groups were not 725 
measured and cannot be ruled out as having an influence on our experimental 726 
measures, it is well established that disuse alone fails to account for the skeletal 727 
muscle impairments developed during heart failure (Simonini et al., 1996; Miller et al., 728 
2009). While we saw a trend for fatigue to be higher in HFpEF under our matched-729 
initial force protocol, this was only performed in n=4 and thus may have been 730 
underpowered to detect statistical, rather than biologically meaningful differences. 731 
Furthermore, as with all biological models, inherent limitations should be considered 732 
and our estimated muscle PO2 values from this study were based on a number of 733 
assumptions (as detailed in Methods) and may not be directly comparable to humans 734 





Obese-HFpEF rats have a blunted hindlimb blood flow response to contractions 738 
alongside microvascular structural remodelling, fibre atrophy, and isotonic contractile 739 
dysfunction, which may be important factors underlying exercise intolerance in this 740 
disease. In contrast, diaphragm phenotype was largely preserved, indicating a more 741 
prominent role for limb rather than respiratory muscle abnormalities in obese-HFpEF.  742 
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Figure Legends 1103 
  1104 
Figure 1. Cardio-metabolic characteristics. At 20 weeks of age, HFpEF rats 1105 
developed obesity (426.2515.41 vs. 529.8829.56 g P<0.001) (A), hyperglycaemia 1106 
(8.381.69 vs. 19.103.83 mmol/L; p<0.001) (B) and hypertension (154.2611.28 vs. 1107 
172.0312.26 mmHg; P=0.012) (C). Compared to lean controls, obese HFpEF rats 1108 
also showed increased right ventricular (RV) wall thickness (0.740.04 vs. 0.820.04 1109 
mm; P=0.034) (D), however left ventricular (LV) wall and the septum thickness were 1110 
not different between groups (2.680.51 vs. 2.550.46 mm; P=0.719 and 2.220.38 1111 
vs. 2.160.49 mm; P=0.849, respectively) (E-F). Left and middle panel: Long axis cuts 1112 
(left) and short axis slices (middle) of representative lean (G) and obese (H) hearts, 1113 
with myocyte helix (inclination) angle colour coded on the cut surfaces. Right panel: 1114 
The helix angle in the RV free wall plotted as a function of fractional transmural 1115 
distance (0.0, endocardium; 1.0, epicardium) for representative lean (G) and obese 1116 
(H) hearts. The red solid line is a 5th order polynomial fit to the data. Myocyte disarray 1117 
is quantified by the R2 of this fit.  1118 
  1119 
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Figure 2. Histological features of the soleus muscle. Obese HFpEF showed 1120 
atrophy in the soleus muscle, with reduced wet muscle mass (206.5415.48 vs. 1121 
152.5012.55 mg; P<0.001) (C) and reduced CSA in both Type I (3921.88316.51 vs. 1122 
3009.75298.03 µm2; P<0.001) and Type IIa fibres (3351.43422.09 vs. 1123 
2575.69296.86 µm2; P=0.001) (D). HFpEF rats also had a lower numerical and areal 1124 
composition of Type I fibres (95.492.45 vs. 87.845.32 %; P=0.002 and 96.062.17 1125 
vs. 84.0615.14 %; P=0.043, respectively), whereas these were higher in Type IIa 1126 
fibres (4.512.45 vs. 12.165.32 %; P=0.002 and 3.942.17 vs. 10.745.31 %; 1127 
P=0.005, respectively) (E-F). Moreover, compared to lean controls, obese rats had 1128 
reduced C:F (2.370.26 vs. 1.960.13; P=0.002) (G), whereas CD was increased 1129 
(438.2357.66 vs. 505.551.53 mm-2; P=0.027) (H) with no change in CDA 1130 
(2363.28410.48 vs. 2024.48223.24 µm2; P=0.059) (I). Finally, local analyses of 1131 
capillary distribution showed that HFpEF rats had lower LCFR in Type I fibres 1132 
(1.780.22 vs. 1.530.10; P=0.011), although this was unchanged in Type IIa fibres 1133 
(1.430.27 vs. 1.240.21; P=0.154) (J). In contrast, LCD in Type I fibres was increased 1134 
in HFpEF rats (440.4159.71 vs. 510.1554.9 mm-2; P=0.029), with no changes in 1135 
Type IIa fibres (423.2088.64 vs. 474.7356.17 mm-2; P=0.196) (K). 1136 
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Figure 3. Modelling of soleus muscle oxygen tension. Simulation of muscle PO2 1140 
at rest (A-B) and maximal rate of oxygen consumption (D-E) in representative images. 1141 
There were no significant differences in simulations of muscle PO2 at rest (Type I 1142 
fibres: 27.260.33 vs. 27.540.30 mmHg; P=0.099, Type IIa: 27.120.39 vs. 1143 
27.370.31 mmHg; P=0.167, all fibres: 27.250.33 vs. 27.520.29 mmHg; P=0.102) 1144 
(C) or at maximal rate of oxygen consumption (Type I: 18.971.38 vs. 20.111.27 1145 
mmHg; P=0.109, Type IIa: 18.001.64 vs. 19.071.36 mmHg; P=0.177, all fibres: 1146 
18.921.36 vs. 20.021.24 mmHg; P=0.115) (F). Areas of muscle hypoxia (PO2<0.5 1147 
mmHg) are highlighted in blue.  1148 
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  1150 
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Figure 4. In vitro skeletal muscle function. The soleus of HFpEF rats showed lower 1151 
absolute twitch force (28.793.23 vs. 20.013.10 g; P<0.001) (A) and absolute 1152 
maximal tetanic force (178.9526.18 vs. 139.3717.05 g; P=0.005) (B), although 1153 
mass-specific twitch and maximal forces were similar between groups (3.360.50 vs. 1154 
2.860.39 N/cm2; P=0.056 and 20.722.28 vs. 19.982.29 N/cm2; P=0.557, 1155 
respectively) (C-D). Similarly, time to peak tension and half relaxation time remained 1156 
unchanged (23.102.25 vs. 22.182.75 ms; P=0.474 and 41.6816.33 vs. 1157 
46.0816.70 ms; P=0.603, respectively) (E-F). However, HFpEF rats showed 1158 
impairments in shortening velocity and muscle power when measured across different 1159 
percentages of their maximal force (30, 40 and 50%) (P<0.05) (G-H). 1160 
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Figure 5. In situ EDL contractile function and femoral artery blood flow. Absolute 1163 
twitch and maximal tetanic forces of the EDL muscle were lower in HFpEF rats than 1164 
in controls (57.2413.82 vs. 41.6211.31 g; P=0.016 and 224.6466.36 vs. 1165 
151.3845.45 g; P=0.030, respectively) (B-C). However, when normalised to muscle 1166 
mass, which was reduced in HFpEF rats (262.8822.47 vs. 194.7315.35 mg; 1167 
P<0.001) (A), these were not significantly affected (0.220.05 vs. 0.220.07 g/mg 1168 
EDL; P<0.968 and 0.820.23 vs. 0.770.21 g/mg EDL; P=0.675, respectively) (D-E). 1169 
The fatigue index was similar between groups (0.460.12 vs. 0.510.09 %; P=0.325) 1170 
(F). However, HFpEF rats tended to be more fatigable during the force-matched 1171 
protocol (45.9611.96 vs. 34.3512.08; P=0.079) (G). Resting femoral artery blood 1172 
flow was augmented in HFpEF rats (1.710.33 vs. 2.660.90 ml/min; P=0.039) (H). In 1173 
contrast, HFpEF rats showed an impaired increase in muscle-specific EDL blood flow 1174 
during stimulation (2.591.30 vs. 0.690.37 ml/min/g; P=0.012) (I). Moreover, a 1175 
reduction in the functional hyperaemic scope was also found in HFpEF (3.221.12 vs. 1176 
1.270.15; P=0.004) (J).  1177 
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Figure 6. Histological features of the diaphragm. Compared to lean controls, 1180 
HFpEF rats had increased CSA in Type I (1130.6730.45 vs. 1647.83286.52 µm2; 1181 
P<0.001) and Type IIa fibres (1352.19133.46 vs. 1709.33273.24 µm2; P=0.005), 1182 
whereas CSA of Type IIb/IIx fibres was reduced (3109.90222.49 vs. 2418.50514.36 1183 
µm2; P=0.004) (C). HFpEF rats also had a higher numerical percentage of Type I fibres 1184 
(32.933.46 vs. 38.382.64 %; P=0.003), although this remained unchanged in Type 1185 
IIa (34.414.39 vs. 30.656.67 %; P=0.203) and IIb/IIx fibres (32.633.43 vs. 1186 
31.006.63 %; P=0.545) (D). Additionally, HFpEF rats showed a higher area 1187 
percentage of Type I fibres (20.262.37 vs. 33.123.85 %; P<0.001), whereas this 1188 
was unchanged in Type IIa fibres (25.383.50 vs. 27.667.47 %; P=0.449) and 1189 
reduced in Type IIb/IIx fibres (54.363.83 vs. 39.2310.33 P=0.002) (E). HFpEF rats 1190 
also showed general and local alterations in capillary distribution. General changes 1191 
included increased C:F (1.96 0.12 vs. 2.260.28; P=0.015) (F) and CD 1192 
(733.4251.94 vs. 822.30104.43 mm2; P=0.049) (G), although CDA remained 1193 
unchanged (1600.57371.08 vs. 1420.58392.25 µm2; P=0.362) (H). Local changes 1194 
included increased LCFR in Type I (0.920.08 vs. 1.390.14; P<0.001) and Type IIa 1195 
fibres (1.050.04 vs. 1.510.16; P<0.001) and reduced LCFR in glycolytic/Type IIb/IIx 1196 
fibres (2.130.21 vs. 1.780.37; P=0.040) (I). In contrast, however, HFpEF rats had 1197 
increased LCD in Type IIb/IIx fibres (615.8545.69 vs. 700.8597.37 mm2; P=0.042), 1198 
with no changes in Type I (765.2660.76 vs. 843.27132.38 mm2; P=0.152) and Type 1199 
IIa fibres (763.7868.71 vs. 842.75119.64 mm2; P=0.128) (J).  1200 
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Figure 7. Modelling of diaphragm oxygen tension. Simulation of muscle PO2 at rest 1203 
(A-B) and maximal rate of oxygen consumption (D-E) in representative images. 1204 
Compared to lean controls, HFpEF rats showed higher muscle oxygen tension at rest 1205 
(Type I fibres: 28.090.39 vs. 28.450.24 mmHg; P=0.043, Type IIa: 27.800.52 vs. 1206 
28.350.27 mmHg; P=0.019, Type IIb/IIx: 27.260.70 vs. 28.130.29 mmHg; 1207 
P=0.006, all fibres: 27.550.61 vs. 28.280.27; P=0.009) (C) or at maximal rate of 1208 
oxygen consumption (Type I: 22.291.57 vs. 23.761.06 mmHg; P=0.045, Type IIa: 1209 
20.522.27 vs. 22.951.22 mmHg; P=0.018, Type IIb/IIx: 17.333.24 vs. 21.581.39 1210 
mmHg; P=0.004, all fibres: 19.072.78 vs. 22.581.26 mmHg; P=0.006) (F). 1211 
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Figure 8. Functional properties of the diaphragm. Isometric twitch and tetanic 1214 
stress of the diaphragm were not different between groups (7.242.87 vs. 8.832.47 1215 
N/cm2; P=0.254 and 23.096.56 vs. 27.467.22 N/cm2; P=0.225, respectively) (A-B). 1216 
In contrast, HFpEF rats showed slowed time to peak tension (16.481.29 vs. 1217 
18.501.21 ms; P=0.006) (C), although half relaxation time was not significantly 1218 
affected (19.303.68 vs. 21.452.02 ms; P=0.170) (D). There were no differences in 1219 
maximal shortening velocity (Vmax) (9.101.11 vs. 8.321.46 Lo/s; P=0.278) (E) or peak 1220 
isotonic power (212.56 59.28 vs. 226.1169.36 W/kg; P=0.701) (F) between groups. 1221 
During cyclical contractions, while the net power-cycle frequency relationship 1222 
remained unaltered between groups (P>0.05); typical work loops are shown at each 1223 
cycle frequency for each group (G), relative fatigue was greater in HFpEF (P<0.001) 1224 
under cycles 6-12 (H).  1225 








